Cardiothoracic Sale Contemplated As Genzyme Ends Tracking Stock Strategy
This article was originally published in The Gray Sheet
Executive Summary
Genzyme Biosurgery plans to divest the bulk of its cardiothoracic devices business by year-end to focus on its orthopedics and biosurgical specialties units
You may also be interested in...
Merit Medical Pumped By J&J Cypher Introduction, Shares Up 37% In July
Merit Medical already has experienced 20% revenue growth for inflation devices related to increased cath lab activity, helping spur investor confidence in the firm's ability to cash in on the drug-eluting stent market
Merit Medical Pumped By J&J Cypher Introduction, Shares Up 37% In July
Merit Medical already has experienced 20% revenue growth for inflation devices related to increased cath lab activity, helping spur investor confidence in the firm's ability to cash in on the drug-eluting stent market
Genzyme Biosurgery
Shareholders file for temporary injunction in New York federal court June 2 against a forced re-integration of the unit with parent firm Genzyme Corp. via a stock swap proposed May 8. Genzyme Corp. holds that the elimination of the separate tracking stocks for Genzyme Biosurgery and Genzyme Molecular Oncology is consistent with provisions of its corporate charter. Biosurgery shareholders allege that Genzyme Corp. delayed release of certain information that would have translated into a higher sale price, including plans to sell Biosurgery's cardiothoracic unit, in order to get a business worth "at least $1.5-$2 bil. for a mere $72 mil." in stock. The re-integration is slated for June 30 (1"The Gray Sheet" May 19, 2003, p. 21)...